Phase I evaluation of seliciclib (R-roscovitine), a novel oral cyclin-dependent kinase inhibitor, in patients with advanced malignancies-Reference-Cited by-同舟云学术

Phase I evaluation of seliciclib (R-roscovitine), a novel oral cyclin-dependent kinase inhibitor, in patients with advanced malignancies

Published:2010-12 Issue:18 Volume:46 Page:3243-3250
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Le Tourneau Christophe,Faivre Sandrine,Laurence Valérie,Delbaldo Catherine,Vera Karina,Girre Veronique,Chiao Judy,Armour Sian,Frame Sheelagh,Green Simon R.,Gianella-Borradori Athos,Diéras Veronique,Raymond Eric

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference25 articles.

1. Roscovitine and other purines as kinase inhibitors. From starfish oocytes to clinical trials;Meijer;Acc Chem Res,2003

2. Role of the INK4a locus in tumor suppression and cell mortality;Serrano;Cell,1996

3. The prognostic significance of altered cyclin-dependent kinase inhibitors in human cancer;Tsihlias;Annu Rev Med,1999

4. The retinoblastoma protein pathway in cell cycle control and cancer;Bartek;Exp Cell Res,1997

5. In vitro and in vivo antitumor properties of the cyclin dependent kinase inhibitor CYC202 (R-roscovitine);McClue;Int J Cancer,2002

Cited by 148 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. ERK5 suppression overcomes FAK inhibitor resistance in mutant KRAS-driven non-small cell lung cancer;EMBO Molecular Medicine;2024-09-13

2. Molecular docking approach for the design and synthesis of new pyrazolopyrimidine analogs of roscovitine as potential CDK2 inhibitors endowed with pronounced anticancer activity;Bioorganic Chemistry;2024-06

3. Ibulocydine Inhibits Migration and Invasion of TNBC Cells via MMP-9 Regulation;International Journal of Molecular Sciences;2024-06-01

4. Recent Discovery and Development of Inhibitors that Target CDK9 and Their Therapeutic Indications;Journal of Medicinal Chemistry;2024-04-02

5. Recent Advances in Structural Optimization of Quinazoline-Based Protein Kinase Inhibitors for Cancer Therapy (2021–Present);Molecules;2024-02-16